For Healthcare Professionals
Help your lymphedema patients improve their quality of life—in the convenience of their own home.
Lymphedema and chronic venous insufficiency pose a unique set of challenges for clinicians and patients. There is currently no cure for these chronic progressive conditions and, if left untreated, they can lead to cellulitis (recurrent infections), fibrosis (progressive hardening and thickening of the skin), decreased mobility and dexterity, and increased pain.
We are here to help.
As your partner, we extend the reach of your comprehensive care into the home. We encourage you to explore our clinically proven products and learn what you can do to help your patients live a better life.
JAMA DERMATOLOGY STUDY HIGHLIGHTS
reduction in cellulitis episodes1a
reduction in physical therapy visits1b
reduction in inpatient hospitalizations1b
reduction in overall cost of lymphedema-related care1a
reduction in outpatient hospital visits1b
of patients reported satisfaction with flexitouch2
1.Karaca-Mandic P, Hirsch AT, Rockson SG, Ridner SH. The cutaneous, net clinical, and health economic benefits of advanced pneumatic compression devices in patients with lymphedema. JAMA Dermatol. 2015;151(11):1187–1193. The study analyzed upper and lower extremity lymphedema patients with cancer related (1A) and non-cancer related lymphedema (1B) treated with the Flexitouch System. The study evaluated use of the Flexitouch System as a tool for the treatment of lymphedema. The study documented a reduction in the rate of cellulitis episodes following use of the Flexitouch System for the treatment of lymphedema. The Flexitouch System is not used for nor intended for use to treat cellulitis.
2.Muluk SC, Hirsch AT, Tafe EC. Pneumatic Compression Device Treatment of Lower Extremity Lymphedema Elicits Improved Limb Volume and Patient-reported Outcomes. EJVES. 2013; Vol. 46(4): 480–487.
Helping Lymphedema Patients Help Themselves
by Darren J. Wennen, MBA
An estimated 5-10 million Americans suffer from lymphedema (LE). Cancer and its treatment is usually designated as the leading cause, however, Chronic Venous Insufficiency (CVI) may be the most important predictor in the development of lower extremity LE.
Revised Starling Principle
In 2004, Adamson and colleagues revealed that the effect of capillary oncotic pressure on transvascular fluid exchange is substantially less than predicted from the original Starling model. This discovery prompted a 2010 revision of the Starling principle by Levick and Michel.